Intellia Therapeutics Inc logo

Intellia Therapeutics Inc

NTLA
Healthcare|Biotechnology|USA
$14.21
-1.23 (-7.99%)
Tangible Book
$5.16

About

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Stock Price

+16.9%(1Y)

Pipeline Summary

10 total trials
5
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
Active: 2Recruiting: 4Withdrawn: 1Terminated: 1Completed: 1ENROLLING_BY_INVITATION: 1

Active Trials (6)

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420Hereditary Angioedema
Phase 3Active
Enrollment: 80 participants
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Phase 3Recruiting
Enrollment: 1,200 participants
A Phase 3 Study of NTLA-2001 in ATTRv-PN
NCT06672237Neuromuscular Disease
Phase 3Recruiting
Enrollment: 60 participants
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
NCT05697861Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Recruiting
Enrollment: 72 participants
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789Hemophilia B
Phase 1Phase 2Recruiting
Enrollment: 130 participants
View all 6 active trials →

BioScore

6.4/10
Watchlist

Ownership

Recent Insider Trades

Dulac Edward J IIISELL
2026-07-024,677 shares @ $18
Dube Michael PSELL
2026-07-012,641 shares @ $16.78
BASTA JAMESSELL
2026-03-021,211 shares @ $13.78
Clark ElianaSELL
2026-03-02607 shares @ $13.78
Schultes Birgit CSELL
2026-01-058,508 shares @ $9.21

Recent News

2026-07-10 13:03:18
2026-07-01 14:59:00
2026-06-17 16:31:07
2026-06-17 14:28:58
2026-06-16 16:35:11
Data last updated: Jul 13, 2026, 10:40 AM